← Back to Search

Loop Diuretic

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

Phase 1
Waitlist Available
Led By Anil K, MD
Research Sponsored by Sarfez Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Eligible Conditions
  • Anemia
  • Weight Changes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
change in 24-hour sodium excretion compared to baseline
Secondary study objectives
Changes in body weight

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CHF Patients: ER Torsemide 40 mgExperimental Treatment1 Intervention
CHF patients will be given 40 mg ER Torsemide
Group II: CHF Patients: Furosemide 40 mgActive Control1 Intervention
CHF patients are on 40 mg of Furosemide
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Torasemide
FDA approved

Find a Location

Who is running the clinical trial?

Sarfez Pharmaceuticals, Inc.Lead Sponsor
5 Previous Clinical Trials
128 Total Patients Enrolled
Anil K, MDPrincipal InvestigatorSyngene International
~4 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top